Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
transferrin-pseudomonas exotoxin a conjugate
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intratumoral, Intrathecal, Intravenous
01
Overview
transferrin-pseudomonas exotoxin a conjugate is an immunotoxin composed of human transferrin chemically linked to Pseudomonas exotoxin A (PE). This therapeutic agent is designed to target cells overexpressing the transferrin receptor (TfR or CD71), a protein frequently upregulated in malignant tissues such as glioblastoma multiforme and melanoma to meet increased iron demands. Upon binding to the TfR, the conjugate is internalized through receptor-mediated endocytosis. Within the cell, the PE moiety is released and catalyzes the ADP-ribosylation of elongation factor 2 (EF-2), which halts protein synthesis and induces apoptosis. Research has primarily focused on its application in neuro-oncology, often utilizing convection-enhanced delivery (CED) to bypass the blood-brain barrier.
- Other names
- transferrin-PEtransferrin-Pseudomonas exotoxin A
02
Targets
EEF2 (Eukaryotic elongation factor 2)TFR2 (Transferrin receptor 2)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on transferrin-pseudomonas exotoxin a conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on transferrin-pseudomonas exotoxin a conjugate.